biostudies-literatureUnknown18Hupe M<h4>Background</h4>As no direct comparison is available between drugs to prevent endoscopic postoperative recurrence (POR) in Crohn's disease (CD), hierarchizing these therapeutic options remains challenging.<h4>Objectives</h4>We aimed to compare the effectiveness of treatments to prevent CD endoscopic POR.<h4>Design</h4>Systematic review and network meta-analysis using a random-effects model.<h4>Data sources and methods</h4>We include studies comparing treatments to prevent CD POR according to PRISMA guidelines. The primary endpoint was endoscopic POR (Rutgeerts score ⩾i2). Surface under the cumulative ranking (SUCRA) was used to hierarchize the treatments.<h4>Results</h4>Twenty studies were included (2414 patients). Overall heterogeneity was moderate (τ = 0.34). Ustekinumab (odds ratio (Therapeutic advances in gastroenterology17562848251374240https://www.ebi.ac.uk/biostudies/studies/S-EPMC12484893biostudies-literatureSystematic review and network meta-analysis comparing the efficacy of conventional therapy and biologics to prevent endoscopic postoperative recurrence in patients with Crohn's disease.PMC12484893Pereira BBuisson AHupe MfalseSystematic review and network meta-analysis comparing the efficacy of conventional therapy and biologics to prevent endoscopic postoperative recurrence in patients with Crohn's disease.<h4>Background</h4>As no direct comparison is available between drugs to prevent endoscopic postoperative recurrence (POR) in Crohn's disease (CD), hierarchizing these therapeutic options remains challenging.<h4>Objectives</h4>We aimed to compare the effectiveness of treatments to prevent CD endoscopic POR.<h4>Design</h4>Systematic review and network meta-analysis using a random-effects model.<h4>Data sources and methods</h4>We include studies comparing treatments to prevent CD POR according to PRISMA guidelines. The primary endpoint was endoscopic POR (Rutgeerts score ⩾i2). Surface under the cumulative ranking (SUCRA) was used to hierarchize the treatments.<h4>Results</h4>Twenty studies were included (2414 patients). Overall heterogeneity was moderate (τ = 0.34). Ustekinumab (odds ratio (2025-01-01T00:00:00Z20252026-06-04T02:23:13.944Z2026-05-04T03:13:08.101ZS-EPMC124848934104128110.1177/17562848251374240